{
  "docId": "019de072-ef20-75e9-922b-a59946a49f08",
  "docSlug": "b6265fe9aad535c251b3bd786fc797fa",
  "documentTitle": "BioAtla | Investor Conference Presentation Deck | 15 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 15,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "problem_statement",
  "function": "diagnose_problem",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-ef20-75e9-922b-a59946a49f08/7",
  "deckHref": "/decks/019de072-ef20-75e9-922b-a59946a49f08",
  "deckJsonHref": "/decks/019de072-ef20-75e9-922b-a59946a49f08.json",
  "deckAnchorHref": "/decks/019de072-ef20-75e9-922b-a59946a49f08#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.88,
        "x": 0.06,
        "y": 0.56
      },
      "kind": "list",
      "text": "We have two ongoing Phase 2 studies in sarcoma and NSCLC",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4ab3a80b-6e56-48fd-8657-8c0bc926328d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.88,
        "x": 0.06,
        "y": 0.38
      },
      "kind": "list",
      "text": "Our Phase 1 studies revealed positive clinical signals across sarcoma and NSCLC, demonstrated by durable clinical responses (PFS and PR), and reductions in tumor size",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "96e7e16b-811d-4304-a1c6-9bc155453b90",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.88,
        "x": 0.06,
        "y": 0.74
      },
      "kind": "list",
      "text": "We are excited to advance towards our transition to commercial-stage company while filling a significant unmet medical need for patients with AXL+ solid tumors",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a2b94fd9-b219-4f9c-8c7f-90514edd19b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.88,
        "x": 0.06,
        "y": 0.2
      },
      "kind": "list",
      "text": "Current treatments for AXL+ tumors are insufficient, leading to high recurrence rates, rapid progression, low survival rates, and drug-related toxicities",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b43aa0ca-56cb-4c27-a4c5-9e17745a444e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.12,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "NSCLC, non-small cell lung cancer; PFS, progression-free survival; PR, partial response.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "58b8d033-6b7e-419a-bec7-c8819ac6e4d4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.26,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "to fill unmet medical needs",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f35ea585-bac8-4c27-88dc-02ec5f8f5955",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.68,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Significant opportunity for BA3011 in Sarcoma and NSCLC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2058433c-534a-4b38-8a41-4c55c7489fad",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 7,
      "from": 7,
      "beatId": "ffed4169-5854-4e29-a2a6-165c7ace146f",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem (Identify pain)",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "The deck presents a problem statement on slide 7",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "f124c2ae-e161-40d9-ad82-028c83aa9dba",
      "evidence": "The deck presents a problem statement and agitates it with encouraging Phase 2 Part 1 Topline Interim Analysis Results",
      "position": 0,
      "objective": "What are the consequences of not improving cancer therapy?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}